Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ellinghaus

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
JAMA Oncology|September 19, 2024
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With <i>FGFR</i> RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical TrialRandy F Sweis, Pablo Gajate, Rafael Morales-Barrera, et al.
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA ExpressionCora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
JAMA Oncology|September 19, 2024
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With <i>FGFR</i> RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical TrialRandy F Sweis, Pablo Gajate, Rafael Morales-Barrera, et al.
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA ExpressionCora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
Pageof 4